Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06497127 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Mixed Dyslipidemia
A Phase 2 study of Mixed Dyslipidemia, sponsored by Shanghai Argo Biopharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 14
- Study locations
NCT06497127: Active Phase 2 study of Mixed Dyslipidemia, sponsored by Shanghai Argo Biopharmaceutical Co..
NCT06497127 is a Phase 2 study of Mixed Dyslipidemia that is active but no longer recruiting, run by Shanghai Argo Biopharmaceutical Co.. The registered enrollment target is 145 participants, below the 691-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (79% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06497127, a Phase 2 study of Mixed Dyslipidemia, is active but no longer recruiting, sponsored by Shanghai Argo Biopharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 2 in Patients With Mixed Dyslipidemia
Primary Outcome
Percent change in fasting TG from baseline to Day 180
Conditions Studied
Interventions
- DRUG BW-00112
Study Locations (14)
Florida
- Excel Medical Clinical Trials, LLC, dba Flourish Research - Boca Raton
- East Coast Institute for Research, LLC - Jacksonville
- Clinical Site Partners Leesburg, LLC dba Flourish Research - Leesburg
- Suncoast Research Group, LLC DBA Flourish Research - Miami
- Clinical Site Partners, LLC DBA Flourish Research - Miami
Alabama
- Alliance for Multispecialty Research, LLC - Daphne
- Alliance for Multispecialty Research, LLC - Mobile
Illinois
- Alliance for Multispecialty Research, LLC - Oak Brook
- Alliance for Multispecialty Research, LLC - Park Ridge
Georgia
- East Coast Institute for Research LLC - Canton
Kansas
- Alliance for Multispecialty Research, LLC - Newton
New York
- Icahn School of Medicine at Mount Sinai - New York
Oklahoma
- Alliance for Multispecialty Research, LLC - Norman
Texas
- Clinical Trials of Texas, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
What the registry record for NCT06497127 still lists
NCT06497127 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 691-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Mixed Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which BW-00112 is the first listed.
NCT06497127 lists 14 locations in 8 states (Florida, Alabama, Illinois).
Frequently Asked Questions
What is clinical trial NCT06497127 about?
NCT06497127 is a clinical study titled "A Study in Patients With Mixed Dyslipidemia". A Phase 2 in Patients With Mixed Dyslipidemia
What is the current status of trial NCT06497127?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2024-02-28. Estimated completion is 2028-03-30.
What conditions does trial NCT06497127 study?
This clinical trial studies the following conditions: Mixed Dyslipidemia.
What interventions are being tested in trial NCT06497127?
The interventions under investigation include: BW-00112 (DRUG).
Who is sponsoring clinical trial NCT06497127?
This trial is sponsored by Shanghai Argo Biopharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06497127 being conducted?
This trial has 14 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mixed Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
COMPLETED · Phase 2
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI